Baxter International Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
Baxter InternationalDie Umsatzerlöse des Unternehmens werden voraussichtlich um 2.4% pro Jahr zurückgehen, während die jährlichen Gewinne voraussichtlich um 39.8% pro Jahr wachsen werden. Der Gewinn pro Aktie wird voraussichtlich um 41.8% pro Jahr wachsen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 13% betragen.
Wichtige Informationen
39.8%
Wachstumsrate der Gewinne
41.8%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 17.0% |
| Wachstumsrate der Einnahmen | -2.4% |
| Zukünftige Eigenkapitalrendite | 13.0% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 20 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Is Baxter International Inc. (NYSE:BAX) Trading At A 49% Discount?
Sep 05
Baxter- Reiterating Our Buy Rating After A Promising Q2
Aug 07Baxter International (NYSE:BAX) Will Pay A Dividend Of $0.29
Aug 07Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
Jul 23Baxter: Why Investors Should Take Advantage Of The Low Valuation
Jul 16Little Excitement Around Baxter International Inc.'s (NYSE:BAX) Revenues
Jul 12Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
May 30Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
May 14Baxter International: Shares Too Cheap, EPS Growth Ahead With A Possible Spinoff
May 08Capital Allocation Trends At Baxter International (NYSE:BAX) Aren't Ideal
Apr 14Broyhill - Baxter International: Renal Care Spin-Off And Recent Revamp Should Provide Catalysts
Feb 23Baxter International's (NYSE:BAX) Dividend Will Be $0.29
Feb 20Here's Why Baxter International (NYSE:BAX) Has A Meaningful Debt Burden
Jan 28Baxter International (NYSE:BAX) Could Be Struggling To Allocate Capital
Jan 12Baxter International Inc.'s (NYSE:BAX) Prospects Need A Boost To Lift Shares
Dec 28Baxter International: A Cheap Big Pharma Stock With Improving Earnings And +3% Dividend Yield
Dec 12Estimating The Fair Value Of Baxter International Inc. (NYSE:BAX)
Nov 27Is Baxter International (NYSE:BAX) A Risky Investment?
Oct 27Should You Buy Baxter Or DaVita After The Fallout From The Ozempic Trial?
Oct 12There Are Reasons To Feel Uneasy About Baxter International's (NYSE:BAX) Returns On Capital
Sep 21Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
Aug 23Dividend Challengers Review: Baxter International
Aug 14Baxter International (NYSE:BAX) Has Announced A Dividend Of $0.29
Jul 25Baxter International (NYSE:BAX) Has A Somewhat Strained Balance Sheet
Jul 14Baxter International: Hillrom Acquisition Could Be A Tailwind For FCF
Jun 12Returns On Capital At Baxter International (NYSE:BAX) Paint A Concerning Picture
Jun 07Baxter International's (NYSE:BAX) Dividend Will Be $0.29
May 19Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 11,774 | 915 | 1,377 | 1,927 | 8 |
| 12/31/2025 | 11,263 | 686 | 952 | 1,476 | 10 |
| 12/31/2024 | 10,556 | 277 | 1,227 | 1,926 | 9 |
| 9/30/2024 | 15,062 | 121 | 391 | 1,062 | N/A |
| 6/30/2024 | 14,962 | 98 | 518 | 1,174 | N/A |
| 3/31/2024 | 14,892 | -38 | 707 | 1,410 | N/A |
| 12/31/2023 | 14,813 | -76 | 1,034 | 1,726 | N/A |
| 9/30/2023 | 11,379 | 96 | 1,108 | 1,634 | N/A |
| 6/30/2023 | 12,389 | -2,932 | 888 | 1,559 | N/A |
| 3/31/2023 | 14,461 | -2,673 | 837 | 1,482 | N/A |
| 12/31/2022 | 14,506 | -2,666 | 591 | 1,211 | N/A |
| 9/30/2022 | 14,275 | -2,568 | 792 | 1,465 | N/A |
| 6/30/2022 | 13,892 | 876 | 1,159 | 1,850 | N/A |
| 3/31/2022 | 13,396 | 992 | 1,341 | 2,053 | N/A |
| 12/31/2021 | 12,146 | 1,022 | 1,531 | 2,222 | N/A |
| 9/30/2021 | 12,451 | 1,214 | 1,496 | 2,241 | N/A |
| 6/30/2021 | 12,197 | 1,120 | 1,354 | 2,076 | N/A |
| 3/31/2021 | 11,817 | 1,068 | 1,265 | 1,973 | N/A |
| 12/31/2020 | 11,673 | 1,102 | 1,159 | 1,868 | N/A |
| 9/30/2020 | 11,531 | 911 | 1,236 | 1,985 | N/A |
| 6/30/2020 | 11,410 | 924 | 1,416 | 2,176 | N/A |
| 3/31/2020 | 11,526 | 991 | 1,487 | 2,248 | N/A |
| 12/31/2019 | 11,362 | 1,001 | 1,408 | 2,104 | N/A |
| 9/30/2019 | 11,156 | 1,335 | 1,201 | 1,984 | N/A |
| 6/30/2019 | 11,066 | 1,484 | 981 | 1,739 | N/A |
| 3/31/2019 | 11,060 | 1,505 | 929 | 1,698 | N/A |
| 12/31/2018 | 11,099 | 1,552 | 1,286 | 2,017 | N/A |
| 9/30/2018 | 11,063 | 1,065 | 1,020 | 1,699 | N/A |
| 6/30/2018 | 11,009 | 795 | N/A | 1,848 | N/A |
| 3/31/2018 | 10,763 | 840 | N/A | 2,095 | N/A |
| 12/31/2017 | 10,584 | 609 | N/A | 1,714 | N/A |
| 9/30/2017 | 10,432 | 1,025 | N/A | 2,036 | N/A |
| 6/30/2017 | 10,283 | 904 | N/A | 1,963 | N/A |
| 3/31/2017 | 10,263 | 1,852 | N/A | 2,176 | N/A |
| 12/31/2016 | 10,163 | 4,966 | N/A | 1,654 | N/A |
| 9/30/2016 | 10,121 | 4,909 | N/A | 1,665 | N/A |
| 6/30/2016 | 10,050 | 4,784 | N/A | 1,388 | N/A |
| 3/31/2016 | 9,940 | 3,646 | N/A | 1,342 | N/A |
| 12/31/2015 | 9,968 | 393 | N/A | 1,771 | N/A |
| 9/30/2015 | 10,154 | 337 | N/A | 2,190 | N/A |
| 6/30/2015 | 10,376 | 510 | N/A | 2,849 | N/A |
| 3/31/2015 | 9,274 | 84 | N/A | 2,752 | N/A |
| 12/31/2014 | 10,719 | 457 | N/A | 3,215 | N/A |
| 9/30/2014 | 12,252 | 739 | N/A | 3,155 | N/A |
| 6/30/2014 | 13,253 | 1,092 | N/A | 3,207 | N/A |
| 3/31/2014 | 15,367 | 1,967 | N/A | 3,371 | N/A |
| 12/31/2013 | 9,413 | 315 | N/A | 3,198 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: BAXDas prognostizierte Gewinnwachstum (39.8% pro Jahr) liegt über der Sparquote (2.6%).
Ertrag vs. Markt: BAXDie Erträge des Unternehmens (39.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.4% pro Jahr).
Hohe Wachstumserträge: BAXEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: BAXDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-2.4% pro Jahr).
Hohe Wachstumseinnahmen: BAXDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-2.4% pro Jahr).
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: BAXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (13%).